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Accountability and Generating 
Evidence for Global Health: 
Misoprostol in Nepal*
Jeevan Raj Sharma, Rekha Khatri and Ian Harper
Abstract Postpartum haemorrhage (PPH) is a major cause of maternal 
morbidity and mortality in Nepal. Compounded by the remote terrain, 
endemic poverty, and a lack of access to health facilities, the use of 
misoprostol has advantages over the standard use of oxytocin for PPH 
management. Drawing on our qualitative study of a pilot intervention 
managed by the Nepal Family Health Programme, we map the institutional 
relationships involved in the design, implementation, and practices 
for bringing misoprostol into national policy. In the intense and competitive 
global and national policy arena, sustained lobbying and getting the ‘right 
people’ on board were as powerful drivers as the quality of the intervention 
itself. The case study takes us to the heart of the debate around the politics 
of generation of evidence for interventions in global health programmes, 
and ultimately the question of accountability for health policy and practice.
Keywords: maternal health, accountability, evidence, health policy, 
Nepal, misoprostol, development.
1 Introduction
Postpartum haemorrhage (PPH) is a major cause of  maternal morbidity 
and mortality in Nepal and in the global South. It is estimated that 
about a quarter of  maternal deaths are caused by PPH (Rushwan 2011; 
Say et al. 2014). Misoprostol is a drug that causes the uterus to contract 
and thus stop PPH (Allen and O’Brien 2009). In May 2011, the 
World Health Organization (WHO) 18th Expert Committee on the 
Selection and Use of  Essential Medicines approved the inclusion of  
misoprostol for the prevention of  PPH in settings where injectable 
uterotonics,1 mainly oxytocin, are not available or feasible (Chu, 
Brhlikova and Pollock 2012). In this article we explore, in the context 
of  Nepal, a programmatic intervention set up to demonstrate the 
feasibility of  misoprostol distribution by female community health 
volunteers (FCHVs) run prior to WHO approval. As a part of  the 
Biomedical and Health Experimentation in South Asia (BHESA) 
research project conducted in Nepal, India, and Sri Lanka between 
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2010 and 2013, we investigated a pilot intervention carried out under 
a bilateral programme of  the United States Agency for International 
Development (USAID) and the Government of  Nepal that took place in 
Nepal’s Banke District between 2005 and 2007. At the time of  our field 
research, this had already been incorporated into national policy.
We began by researching the individuals, organisations, and 
institutional arrangements that were responsible for bringing the idea 
of  misoprostol to Nepal, managing this pilot intervention and lobbying 
for its scaling up into national policy. This included mapping the role of  
organisations and individuals and their key relationships and networks 
in this process. We looked through the webpages of  all the organisations 
involved in the bilateral programme managing the pilot intervention, 
and collated their publications including reports, technical briefs, and 
two academic articles that were published in 2006 and 2010 in the 
International Journal of  Gynecology & Obstetrics. We carried out interviews 
with staff members and consultants involved in this initiative, and 
government staff who were directly involved in the pilot and its scaling 
up into policy. We also conducted ethnographic fieldwork in Banke 
District where the pilot intervention took place, and interviewed staff at 
the District Health Office, health workers in sub-health posts, as well as 
FCHVs who were involved.
Our aim was to chart the considerable work done by the individuals and 
organisations, and understand their relationships and networks during 
the process of  getting misoprostol into national policy. We reveal how in 
the intense and competitive policy arena, sustained lobbying and getting 
the ‘right people’ on board were as powerful drivers as the quality of  the 
intervention itself. Underlying the intervention were strong ideological 
drivers and the vested interests of  USAID, WHO, and international 
research organisations, and complex national and international 
organisational politics.
Central to these relationships and their configurations is the question 
of  accountability. In our view, there are two ways to think about 
accountability in the context of  this empirical research. First, the global 
health landscape and associated accountability structures is increasingly 
complex, with the entanglement of  public and private actors (Horton 
2014; Bruen et al. 2014). The involvement of  chains of  private actors 
that mediate the relationship between global health policies and local 
populations raises critical questions on overlapping and competing 
mandates (Sharma et al. 2017) as well as risks involved with diluting 
responsibility across a broadening set of  actors (Bruen et al. 2014). Who 
should be accountable for global health programmes that involve a 
large number of  actors with varying degrees of  power and influence? 
How should the relationships of  accountabilities be worked out amongst 
different actors, including funding agencies, host governments and their 
ministries, the implementing agencies (be that primary health-care 
providers from government and/or non-governmental organisations 
(NGOs)), and the recipient populations?
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Second, accountability concerns within global health programmes are 
being informed by new norms such as value for money and measurable 
results as a way to address accountability (Fan and Uretsky 2017). 
There is increased economic and political pressure to demonstrate the 
impact of  projects and programmes in terms of  demonstrating that the 
disbursement of  resources is tied to measurable results (Horton 2014; 
Valters and Whitty 2017). This has given rise to new institutional forms 
including monitoring and evaluation and the critical importance of  
generating evidence within programmes. Not only are programmes 
increasingly organised as a set of  measurable results, with costs 
directly linked to the achievement of  those measurable results, they 
are also increasingly organised around ‘pilot’ interventions. Essentially, 
these shifting norms shape the very idea of  health and how health 
programmes should be designed and implemented. In this sense, the 
ideas associated with accountability are shaping the way we define the 
problem, prioritise the interventions, and measure their outcomes.
Thus, this case study takes us to the heart of  the debate around the politics 
of  generation of  evidence for interventions in global health programmes, 
and ultimately the question of  accountability for health policy and 
practice. It is an example of  but one programmatic intervention being 
undertaken in Nepal, reflecting the increasing complexity of  constellations 
of  organisations involved in the provision of  health services. A final caveat 
is methodological. We do not make normative claims or suggestions for 
change to accountability mechanisms, or ascribe normative judgements 
(be these ideological, ethical, or political). Our approach is ethnographic, 
and we provide this case study as a way to think where we place the 
primacy of  responsibility: either at the level of  the state, or with bilaterals 
that fund, or with NGOs in this context.
2 Background
PPH is defined as loss of  greater than 500ml of  blood following within 
24 hours of  vaginal delivery (WHO 2009). Given widespread poverty, 
anaemia, unequal gender relations, remote terrain, and limited access 
to health facilities resulting in high numbers of  home deliveries without 
skilled birth attendants (SBAs), PPH is a major cause of  maternal death 
in Nepal and much of  the developing world (Rushwan 2011; Say et al. 
2014; Suvedi et al. 2009).
Endorsed by WHO, oxytocin is the preferred option for the 
management of  postnatal care but it needs to be administered by 
injection by a health professional, and requires a cold chain for storage 
(Chu et al. 2012). Thus, whilst effective, this limits its use practically 
(Prata, Bell and Weidert 2013). Despite considerable efforts to increase 
institutional delivery in Nepal, including new innovations such as 
maternity incentive programmes,2 the institutional delivery rate stood at 
35 per cent in 2011 (MOHP, New ERA and ICF International 2012).
Misoprostol was developed by SEARLE (now Pfizer) in 1973. The 
US Food and Drug Administration (FDA) first registered it in 1988 for 
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the treatment of  gastric ulcers (Millard, Brhlikova and Pollock 2015). 
It was also found to cause the uterus to contract, which is why it is 
considered as an option to stop PPH, and was increasingly used ‘off-
label’ for different purposes (ibid.). More importantly, unlike oxytocin, 
it can be taken orally, sublingually, or vaginally, and does not require 
a cold chain for its storage, and thus it is considered by some to be a 
suitable option in the absence of  skilled medical professionals. For these 
reasons, it is thought to be a suitable solution for the management of  
PPH in low-income settings (ibid.). In the last two decades, there have 
been a large number of  pilot interventions in low-income countries 
such as Nepal that assess misoprostol’s efficacy and the feasibility of  
distribution by community health volunteers (ibid.).
Jhpiego conducted the first study on community-based distribution of  
misoprostol in Indonesia (Sanghvi et al. 2004). The purpose of  this study 
was ‘to demonstrate the safety, acceptability, feasibility, and program 
effectiveness (SAFE) of  community-based distribution and use of  oral 
misoprostol to reduce PPH in areas where a large proportion of  births 
are not attended by skilled providers’ (Sanghvi et al. 2004: viii). As we 
were told by a senior official at Jhpiego, they wanted to take ‘misoprostol 
treatment outside of  the formal system’. It showed dramatic impact. 
Although interestingly this was never published, the results were widely 
disseminated at a meeting in 2004, and were widely cited, and – we were 
informed – therefore ‘didn’t really need publication’.3
As is apparent from cautionary statements put out by WHO, their 
resistance to the use of  misoprostol was mainly threefold: first, against 
the ideas of  self-administering; second, concern with the as-of-yet 
unreported side effects of  the drug (for example, uterine rupture if  
taken too early). One of  the publications advocating WHO’s cautionary 
approach quoted Sir Iain Chalmers: ‘Because professionals sometimes 
do more harm than good when they intervene in the lives of  other 
people, their policies and practices should be informed by rigorous, 
transparent, up-to-date evaluations.’4 And third, as reiterated in the 
interviews we conducted, that it would detract from the use of  SBAs. 
The subsequent approval of  misoprostol by WHO in May 2011 has 
increased promotion for community-based distribution in low-income 
countries, although the scientific evidence has been contested.5
Called ‘matrisurakchya chakki’ in Nepali (literally translated as ‘safety tablet 
for mothers’), the push for its widespread use was directly stimulated by 
targets for Millennium Development Goal 5, and is embedded in the 
rise of  metrics and measurement in global health programmes (Adams 
2016). This discourse is driven by ‘magic bullet’ solutions to complex 
global health challenges. In addition, scholars have commented on 
the role of  networks of  organisations and individuals with substantial 
financial and political backing from major foundations, in influencing 
WHO’s decision to include misoprostol in its Essential Medicines 
List (Millard et al. 2015), and the role of  civil society organisations in 
Uganda (Atukunda et al. 2015). In this article, we offer an ethnography 
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of  how misoprostol made it into Nepal’s national health policy as a 
part of  a pilot intervention despite resistance from WHO. We offer 
an analysis of  how sustained lobbying and getting the right people on 
board were critical in this process.
3 Evidence generation in the health sector in Nepal
Elsewhere we have charted the history of  scientific research in the 
health sector in Nepal and its close ties to development aid (Sharma, 
Khatri and Harper 2016). Much of  this research activity in the health 
sector is sponsored by bilateral aid agencies such as USAID and/or 
carried out by development institutions, often in collaboration with 
universities and research institutions. Not only have the discourses on 
evidence become central in proposing solutions to health challenges, 
health programme interventions are increasingly designed to generate 
evidence. With organisations like the Global Fund, for example, 
demanding that the resources are now dispersed based on performance 
linked to indicators, this increasingly drives how organisations design 
their programmes.6 Thus, the accountability and results agenda in 
global development and health debates have directly shaped these forms 
of  interventions (Adams 2016; Valters and Whitty 2017).
This form of  generation of  evidence around programmatic 
interventions has been sustained by assemblages of  local and 
international organisations and universities, and supported and funded 
by aid institutions. These assemblages and institutional forms involving 
donors and their advisors (bilaterals; international non-governmental 
organisations (INGOs)), government policymakers, programme 
managers working for governments, INGOs, and NGOs, and 
researchers are not only critical in the generation of  evidence but also 
provide much-needed networks of  support for the successful up-scaling 
of  pilot projects (Sharma et al. 2016; Harper 2014). In Nepal, several 
NGOs and a few private research firms specialising in health systems 
research have emerged that mainly work on short-term sub-contractual 
agreements with the government, bilateral, multilateral, and private 
philanthropic organisations.7
Given the small number of  these institutions, reflecting the limited 
research capacity in-country, they are often oversubscribed by the 
sponsors. The short-term nature of  the contracts mean that they are 
constantly busy in simultaneously handling multiple projects while 
moving to the next one (ibid.). These evidence generation activities are 
dispersed and hidden under various programmatic interventions and 
it is almost impossible to map all the ongoing activities (Sharma et al. 
2016). There is no clear definition as to what is regarded as health 
research activity and thus what needs approval from the Nepal Health 
Research Council (NHRC) and what does not. The misoprostol pilot 
intervention that this article reflects on did secure NHRC approval.
Given this background, Section 4 examines the specific institutional 
arrangements around the introduction of  misoprostol.
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4 Institutional arrangements
In Nepal, the network to introduce misoprostol into the government’s 
national programme coalesced around the Nepal Family Health Program 
(NFHP). It has broad aims, particularly to support the Government of  
Nepal’s goals of  decreasing fertility and under-five mortality, through 
providing basic family planning, and maternal and child health services.
This has involved the following partners, for phase 1 (2002–07): John 
Snow Inc. (JSI); EngenderHealth; Johns Hopkins University/Center 
for Communication Program (JHU/CCP); Jhpiego; CARE; Save the 
Children Federation/US (SCF/US); the Nepal Fertility Care Center 
(NFCC); the Nepali Technical Assistance Group (NTAG); Management 
Support Services (MASS); and the Adventist Development and 
Relief  Agency (ADRA).8 And for phase 2 (2007–12): JSI Research 
and Training Institute (RTI), and its partners – Save the Children; 
EngenderHealth; Jhpiego; World Education; NTAG; NFCC; MASS; 
the Nepal Red Cross Society; the United Mission to Nepal; the BBC 
World Service Trust; the Digital Broadcast Initiative Equal Access 
Nepal; and the Family Planning Association of  Nepal.9
This ostensibly bilateral programme funded by USAID had its own office, 
separate from the Ministry of  Health. Its well-furnished offices and staffing 
conditions by far exceeded the budget of  government departments. One 
senior member in NFHP described it as ‘a consortium of  different parties’ 
– not registered as a different organisation, and staff are paid by different 
partners.10 Thus NFHP was not an NGO, government department, or a 
unit of  USAID; it was essentially a consortium of  several key organisations 
that brought together different expertise on technical knowledge on 
maternal health, logistics, and communications. It had significant leverage 
in health systems development in Nepal.
Accountability fell to both USAID and the Government of  Nepal. 
NFHP management had to report to USAID. As a bilateral programme, 
NFHP had the authority of  the Government of  Nepal, although it 
sat outside of  the government structure. Although the activities of  
NFHP were carried out through the government structure and with 
the engagement of  government staff, these staff did not have leading 
roles in shaping the programme. In other words, the government was 
accountable for the programme, although NFHP project staff largely 
carried out its activities. NFHP had a budget of  about US$25m. It had 
hired a number of  highly experienced expatriates as well as Nepali 
professionals with deep knowledge of  the health system and service 
provision in Nepal. Many of  the employees were former employees of  
the government, or had been employees in phased-out USAID-funded 
projects with the required skills and relationships for navigating the 
health system. At the time of  our fieldwork, the team leader of  NFHP 
was hired under EngenderHealth, a New York-based organisation. 
Some of  the key organisations have headquarters in the US (Jhpiego in 
Baltimore, JSI in Boston, SCF/US in Connecticut with project offices in 
Nepal, Venture Strategies in California). The others are based in Nepal.
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Table 1 details the key organisations, their objectives, and roles in the 
NFHP consortium.
Table 1 Key organisations in the NFHP consortium
Organisation Main objectives Role in NFHP 
Jhpiego11 Promotes practical, low-cost innovations 
to improve the health of women and their 
families
Technical support and training 
EngenderHealth12 Develops private sector involvement, 
particularly around sexual and reproductive 
health, and promotes social franchise
‘Nepalising’ the training materials
John Snow Inc. (JSI)13 Improves the health of underserved people 
and communities
Management of logistics
Johns Hopkins University/ 
Center for Communication 
Program (JHU/CCP)14
Mobilises health communications to save 
lives and transform public health system
Development of communications strategy 
and materials
CARE Nepal15 Empowerment of poor, vulnerable, and 
socially excluded people to fulfil their basic 
needs and achieve social justice
Support in the formal handover of health 
facilities to local communities in 17 districts
Save the Children (SCF/US)16 Improves the lives of children worldwide Support in the formal handover of health 
facilities to local communities in 17 districts
Nepal Fertility Care Center 
(NFCC)17
Provides standardised reproductive health 
services across Nepal as well as supporting 
the government by training direct and 
indirect government and NGO health 
personnel 
Technical support on family planning and 
reproductive health services
Adventist Development 
and Relief Agency – Nepal 
(ADRA)18
Creates just and positive change through 
empowering partnerships and responsible 
action
Implementation of the programme in 
selected districts
Valley Research Group 
(VaRG)19
Conducts applied socioeconomic research 
including action research, and offers 
training and consultancy services 
Carries out operational study with a baseline 
and endline survey
Management Support 
Services (MASS)20
Delivers innovative and customised 
management services which include 
logistics planning, supply chain 
management, HR management, 
organisation development, and research 
studies
Financial and organisational management 
Nepali Technical Assistance 
Group (NTAG)21
Enhances technical and management 
capabilities of health personnel working in 
various health programmes 
Technical support on the delivery of 
community-based approaches to the 
programme
Venture Strategies for Health 
and Development (VSHD)22
Stabilise global population by securing 
women’s freedom to choose their family 
size
Lobbying for misoprostol to be registered as 
an essential medicine23,24
Sources See endnotes 11–24.
56 | Sharma et al. Accountability and Generating Evidence for Global Health: Misoprostol in Nepal
Vol. 49 No. 2 March 2018: ‘Accountability for Health Equity: Galvanising a Movement for Universal Health Coverage’
This constellation of  organisations indicates that there is a complex 
relationship between them, their roles and responsibilities (frequently 
in the guise of  ‘technical support’), and the state. Calls for proposals to 
implement programmes are now increasingly issued by USAID, and 
others such as the Department for International Development (DFID) 
(UK aid), and consortia such as these apply.
Having outlined the main organisational arrangements of  NFHP, we 
now turn to the work involved in bringing misoprostol’s programmatic 
presence into Nepal and stabilising it.
5 Misoprostol enters Nepal
Under NFHP, there was considerable work undertaken to bring 
misoprostol to Nepal (see Table 2 for a chronology of  the key dates in 
this process). Initially, the Ministry of  Health was reluctant to start the 
Table 2 Misoprostol in Nepal: key developments
1973 SEARLE (later incorporated into Pfizer) develops misoprostol
1988 FDA registers it for off-label use
2001 NFHP (2001–06) starts in Nepal
2003 NFHP submits published evidence on misoprostol to FHD
2000–03 Jhpiego carries out first pilot of community distribution of misoprostol 
in Indonesia, which gets published in 2004
2004 Jhpiego organises PPH Bangkok meeting – attended by director of FHD 
from Nepal
2004 NESOG Scientific Meeting 
2005 Department of Drug Administration (DDA) approval of drug for pilot
2005 NHRC approval for pilot study
2005 TAG (technical advisory group) meeting makes recommendation to 
National Safe Motherhood and Neonatal Sub-Committee 
2005 Baseline study in Banke, training and pilot intervention starts
2006 Paper from baseline published in International Journal of Gynecology & 
Obstetrics
2007 Endline/follow-up survey in Banke
2007 A follow-up to NFHP, NFHP II (2007–12) starts in Nepal
2008 Misoprostol included in national Essential Drug List (EDL)
2008 Approved for national programme
2012 WHO approves the inclusion of misoprostol for the prevention of PPH 
in settings where parenteral uterotonics are not available or feasible
Source Chu et al. (2012); Hobday et al. (2017); and interviews in Nepal (see 
endnotes 25–45).
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misoprostol pilot.25 It took more than a year for NFHP to convince the 
government. In 2003–04, NFHP staff presented the concept of  using 
misoprostol in various forums in Nepal. Its lobbying included giving 
presentations at the Nepal Society of  Obstetricians and Gynaecologists 
(NESOG) and to other critical stakeholders on maternal health in 
Nepal.26
In 2004, Jhpiego organised a conference in Bangkok to disseminate 
the results of  its study on community-based distribution of  misoprostol 
in Indonesia,27 to which it had invited teams from 18–20 countries.28 
NFHP took a strong team from Nepal led by the director of  the Family 
Health Division (FHD) who committed that Nepal would pilot the 
misoprostol study.29
Following on from this, a senior staff member from Jhpiego shared 
the idea of  using misoprostol in the National Safe Motherhood and 
Neonatal Sub-Committee meeting in September 2004.30 Likewise, 
NFHP facilitated the visit of  an expert on misoprostol from Indonesia, 
who shared the Indonesian experience in the sub-committee meeting.31 
Presentations by these authorities at the FHD were an important part 
of  the lobbying. NFHP worked with the Ministry of  Health to ask for 
the opinion of  NESOG and the Maternity Hospital regarding the use 
of  misoprostol.32 A major constraint in bringing misoprostol to Nepal 
was that the drug was not licensed in Nepal at that time, plus there 
were fears that it could be used for abortion.33 Resistance was an issue 
from the perspective of  the programme director. There was widespread 
speculation that misoprostol use could also deskill SBAs.34 Overcoming 
such resistance was also about having the right political weight behind 
the programme. Therefore, lobbying and networks of  alliances of  
NFHP was critical. Hence, as one senior Nepali researcher argued, 
getting research into policy is about leadership:
I think it’s the leadership. It depends on the leader how he thinks for the country. 
Our Director-General, Dr X is one of  the best in public health and among those 
who understands what is needed for our country. In the beginning, he initiated… 
There were programmes like chlorohexidine and other programmes and we all 
voted for [this programme] and he also felt strongly [about] it. So, when the 
leader says it, it’s not difficult.35
When NFHP started this work, there was no legal provision for medical 
abortion in Nepal36 and therefore the use of  the drug was a sensitive 
issue. But there was a provision that the drug could be imported with 
specific instructions under the recommendation by NESOG. NFHP 
applied to the Department of  Drug Administration (DDA) and also to 
the NHRC for ethical clearance. NFHP held a few meetings with the 
director of  DDA, after which Cipla started dealing with the DDA.37 It 
did not take much time at the NHRC to get the clearance because the 
pilot intervention was seen to be the ‘FHD’s work’.38
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6 Banke pilot intervention
Banke District in the western Terai region of  Nepal was chosen for the 
pilot intervention. This district was regularly used for pilot interventions 
and trials, and so already had experience and an operational research 
infrastructure in place.39
The research study was designed to test the feasibility of  community-
based delivery of  misoprostol by existing public sector community 
health volunteers, with self-administration of  three 200mcg tablets by 
women delivering at home (Rajbhandari et al. 2010).
This PPH-related work was one of  a broader set of  activities, intended 
to improve maternal and neonatal outcomes, implemented by the 
district public health system with support from the Nepal Family 
Health Program (NFHP) funded by the United States Agency for 
International Development (USAID) (Rajbhandari et al. 2010: 283).
In this sense, NFHP already had an infrastructure and relationships set 
up for this pilot intervention.
From USAID’s perspective, it was important that the pilot intervention 
included distribution of  misoprostol through FCHVs, a community-
based unpaid cadre that it has been supporting over the years. As part 
of  its focus on services for and by women, extending services beyond 
the health facilities and promoting maternal and child health, USAID 
has continued to provide technical and financial support for the FCHV 
programme’s expansion (Justice et al. 2016).
Health posts in Banke were painted with the message to use misoprostol. 
A senior official said: ‘We had to picturise shivering (a potential side 
effect) for the flip chart. This was very challenging. Transferring technical 
knowledge was very difficult and it was a turning point for me.’40
Logistics was a major component of  this work and JSI managed all 
the logistics as they had been managing it for the family planning 
programme. NFHP had set up a monitoring and evaluation system, and 
it used highly experienced staff who had served at a well-known research 
organisation – New ERA – for a long time. International consultants 
were hired to help with monitoring and evaluation work.41 The regional 
office of  NFHP was fully dedicated to implementing the project in 
Banke, and provided oversight for misoprostol distribution and other 
community-based maternal–neonatal work.42 The District Public Health 
Office (DPHO) team in Banke was fully involved in supporting the 
implementation of  the project and provided management oversight.
The USAID budget could not be used for buying the misoprostol tablets 
and therefore Plan International Nepal paid for the medicines.43 When 
the tablets came from Cipla, there were four 200mcg tablets in one 
packet. NFHP repackaged them to contain three tablets in one packet 
as the required dose was 600mcg, and also relabelled the packet as 
‘Matri Surakschya Chakki’.
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Government staff trained FCHVs for seven days, of  which three 
days were focused on misoprostol. In addition, as a part of  the pilot 
intervention, household surveys (which included 30 clusters of  30 
households each) were conducted at baseline and at endline. A 
Nepali private research organisation, Valley Research Group, was 
subcontracted to conduct the survey. Baseline fieldwork was done in 
May–June 2005, about six months prior to the implementation of  the 
programme, and the endline survey was done in June–July 2007.
The study found that out of  840 post-intervention survey 
respondents, 73.2 per cent received misoprostol. The standardised 
proportion of  vaginal deliveries protected by the uterotonic rose from 
11.6 per cent to 74.2 per cent (Rajbhandari et al. 2010). The study 
concluded that community-based distribution of  misoprostol for 
PPH prevention can be successfully implemented under government 
health services in a low-resource, geographically challenging setting, 
resulting in much increased population-level protection against PPH 
(Rajbhandari et al. 2010).
7 From evidence to policy
The findings from the Banke intervention were published in the 
International Journal of  Gynecology & Obstetrics in 2006 and 2010 
(Rajbhandari et al. 2006; Rajbhandari et al. 2010). However, as we 
show above, the decision that misoprostol and its community-based 
distribution was the right policy direction had already been made by a 
committed group of  individuals and institutions prior to the publication 
of  results. The key players – the FHD, NESOG, and the DDA – had all 
been involved from the beginning. The process was incremental. Not 
only was the pilot intervention implemented through the government 
system in Banke, but there was considerable work to engage decision 
makers in government offices through frequent working group meetings. 
The health minister had come to Banke to launch the programme. 
The Director-General was very supportive from the outset, and is one 
of  the co-authors of  the article, indicative of  the support levered for 
the intervention.
As we have seen, the role of  NFHP was central to this process. NFHP 
had created the necessary social and political networks to scale up the 
pilot into a national programme. After the successful result from the 
pilot, the programme was implemented in additional districts where 
further partner organisations could monitor and the government had 
begun to take responsibility to implement and monitor without external 
support.44 In March 2010, there was a presentation on misoprostol 
at another conference in Bangkok. The government then committed 
to a national-level programme for misoprostol. An action plan was 
announced and the findings of  the study were further discussed 
in the National Safe Motherhood and Neonatal Sub-Committee 
meeting, supported by the technical advisory group (TAG). The final 
ratified decision to make it a national programme was taken by the 
Ministry of  Health.
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8 Discussion
As shown above, the technical brief  and the journal articles demonstrate 
that the narrative framing was set up to push debate within the health 
sector in Nepal. The intervention also fell firmly within the existing 
drive of  USAID-funded programmes: that not only was it possible 
to run such a programme through the FCHVs, but they actively 
asked for more of  this kind of  work; that the programme reaches the 
disadvantaged segments of  the community (hence hitting the right 
social inclusion discourses, pushed in particular by the World Bank); 
that this intervention is only complementary to the push (mainly by DFID) 
to attempt to increase the institutional delivery of  babies, and where the 
drug sanctioned is the injectable oxytocin, thus attempting to allay these 
fears; and that the pilot intervention had demonstrated that it is possible 
to mobilise the resources and will of  a range of  partners so that rapid 
expansion could occur.
At stake here, we argue, was an ideological disagreement between 
WHO and Jhpiego, and its acolytes: WHO promoted the use of  SBAs 
for delivery and were not on board with the use of  misoprostol. We were 
informed by a senior member of  NFHP that WHO also mentioned 
that if  misoprostol has to be distributed, it must be through the health 
workers, not the community-based volunteers. The research participants 
felt that the difficulty was also because the Nepal government strongly 
adheres to WHO recommendations, and therefore it took quite some 
time to convince the authorities to pilot this study, which was an exercise 
solely intended for policy uptake.45
While Millard et al. (2015) have pointed to the increasing role of  
networks in getting misoprostol onto the WHO Essential Medicines 
List, what they miss in our opinion is the underlying ideological struggle 
that misoprostol was able to lever: the relationship between the power 
of  medical authorities and women; that is, ultimately, a question of  who 
has control. We were informed that the first presentations of  the SAFE 
study were to NESOG in Nepal and other professional societies, such as 
the Nepal Paediatric Society, for this very reason. It was the obstetricians 
and doctors that were particularly against this use of  misoprostol on the 
grounds that the mode of  delivery is crucial, and institutional support 
is a necessity, should anything go wrong, for identifying the side effects, 
etc. It is, however, this very lack of  institutional support through much 
of  rural Nepal that the pro-misoprostol lobby were using in arguing 
for its use. As one interviewee stated in lobbying the use of  FCHVs, 
‘Every question was answered’. Thus it was able to show that here was 
a country ‘reaching an MDG with less than 30 per cent skilled birth 
attendants, and it is community driven!’
Our conclusion from this work is that whether a study becomes policy 
or not ultimately depends on how well the researchers take part in 
the policymaking discourse. Researchers can work on their own and 
disseminate their findings, but successful scaling up depends on the 
strength and relevance of  the political and policy networks of  the 
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research group. Hence, we might argue, as Mosse (2004) has done more 
broadly for development interventions, that the outcome of  policy or 
research is not as important as the generation of  increasingly dense 
networks to sustain these relations and the flow of  resources.
To conclude, the research delved into the interstices of  development 
and health, but also the arena of  where programmatic interventions 
and research intersect. We felt that we could make visible some 
interpretive dimensions on accountability that might have otherwise 
escaped us. This ethnography poses questions as to where to situate 
responsibility and accountability in the context of  overlapping and 
competing mandates between different public and private, and national 
and international organisations, and the degree of  programmatic 
evidence needed. Our work shows how accountability is dissipated 
across the organisations, each of  which has a different role to play 
in the consortium, but is accountable financially to USAID, or their 
board which lies beyond the Nepalese state. In addition, the use of  
pilot projects such as the one we have described, and the increasingly 
evidence-based drive (to persuade at the level of  national policy and for 
sceptics in powerful positions) makes it possible to lay broader claims for 
the model. If  accountability is about laying claims to success and failure, 
then the programmatic pilot intervention mediates this task.
Notes
* This article results from research funded by the Economic and Social 
Research Council–Department for International Development 
[ESRC–DFID] Joint Programme on Poverty Alleviation,  
RES-167-25-0503, under the title ‘Biomedical and Health 
Experimentation in South Asia’ (BHESA). The BHESA project 
team includes partners at the Centre for Studies in Ethics and Rights 
(India), Social Science Baha (Nepal), the University of  Colombo (Sri 
Lanka), the University of  Durham, and the University of  Edinburgh. 
Ethical approval for the study was initially given by the School of  
Social and Political Sciences Research Ethics Committee, University 
of  Edinburgh (13 October 2010). Ethical clearance was then gained 
from the Nepal Health Research Council in Nepal. We thank Roger 
Jeffery for his comments on an early draft of  this article. Neither 
ESRC, DFID nor any of  the partner institutions are responsible for 
the views advanced here.
1 Uterotonics lessen blood loss during childbirth and are very 
important in the prevention and treatment of  PPH.
2 These are financial incentive schemes aimed at assisting women and 
their families with regard to childbearing.
3 Interview with a senior official at Jhpiego, Kathmandu, 12 August 2011.
4 http://apps.who.int/iris/bitstream/10665/70328/1/WHO_
RHR_10.11_eng.pdf.
5 For more on this evidential debate, see Chu et al. (2012).
6 See, for example: www.theglobalfund.org/media/5198/me_monitoring 
andevaluation_brochure_en.pdf ?u=636488964340000000.
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7 The most active local research institutions include New ERA, the 
Valley Research Group, the Center for Research on Environment 
Health and Population Activities, the Health Research and Social 
Development Forum, and the Nepal Public Health Foundation. New 
ERA, for example, was established by three Peace Corps Volunteers 
in 1971, and was the first research firm established to work in Nepal.
8 www.jsi.com/JSIInternet/IntlHealth/project/display.cfm?ctid= 
na&cid=na&tid=40&id=147.
9 http://nfhp.jsi.com/Docs/nfhp_flyer.pdf.
10 Interview with a senior NFHP staff, Kathmandu, 26 August 2011.
11 www.jhpiego.org/who-we-are/our-history/.
12 www.engenderhealth.org/our-countries/asia-near-east/nepal.php.
13 www.jsi.com/JSIInternet/.
14 https://ccp.jhu.edu.
15 www.carenepal.org/.
16 www.savethechildren.org/.
17 www.nfcc.org.np/.
18 www.adranepal.org/.
19 For details, see VaRG (2008).
20 http://mass.com.np/.
21 www.ntag.org.np/.
22 http://venturestrategies.org/. This organisation is a key ‘node’ in 
the international network involved in lobbying WHO to have the 
drug registered for PPH on the WHO Essential Medicines List 
(Millard et al. 2015).
23 www.venturestrategies.org/programs/womens-options/.
24 We received the following information from a VSHD representative 
via email about their lobbying activities in Nepal: ‘In Nepal, my 
organization, VSHD, was investigating the status of  the registration 
of  misoprostol for PPH. We verified that it had been registered by the 
drug company Cipla (Bombay) via Yetichem for PPH very recently, 
perhaps in July. Two registrations, also by Cipla, of  misoprostol for 
abortion preceded the PPH registration. Access to misoprostol is 
quite restricted, however’.
25 Interview A, NFHP staff, Kathmandu, 26 August 2011.
26 Interview B, NFHP staff, Kathmandu, 26 August 2011.
27 Interview A, NFHP staff, Kathmandu, 26 August; Interview, NFHP 
staff, Kathmandu, 12 August 2011.
28 Interview, NFHP staff, Kathmandu, 12 August 2011.
29 Interview A, NFHP staff, Kathmandu, 26 August 2011; Interview, 
NFHP staff, Kathmandu, 12 August 2011.
30 Interview B, NFHP staff, Kathmandu, 26 August 2011.
31 Interview B, NFHP staff, Kathmandu, 26 August 2011.
32 Interview B, NFHP staff, Kathmandu, 26 August 2011.
33 Interview A, NFHP staff, Kathmandu, 26 August 2011.
34 Interview A, NFHP staff, Kathmandu, 22 March 2011.
35 Interview A, NFHP staff, Kathmandu, 29 December 2011.
36 Abortion was made legal in Nepal in 2002.
37 Interview A, NFHP staff, Kathmandu, 26 August 2011.
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38 Interview A, NFHP staff, Kathmandu, 26 August 2011.
39 See, for example, Khanal et al. (2013); VaRG (2005).
40 Interview A, NFHP staff, Kathmandu, 26 August 2011.
41 Interview, NFHP staff, Kathmandu, 12 August 2011.
42 Interview, NFHP staff, Kathmandu, 16 November 2011.
43 Interview A, NFHP staff, Kathmandu, 26 August 2011.
44 Interview, NFHP staff, Kathmandu, 12 August 2011.
45 Interview A, NFHP staff, Kathmandu, 26 August 2011; Interview, 
NFHP staff, Kathmandu, 12 August 2011.
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